Abstract
Paclitaxel is an anticancer drug used in the treatment of ovarian, breast, head and neck, lung, and prostate cancer. We investigated the anti-platelet activity of paclitaxel in vitro as well as a possible anti-platelet mechanism. Paclitaxel inhibited washed rabbit platelet aggregation induced by collagen in a concentration-dependent manner, with an IC50 of 59.7 ± 3.5. However, it had little effect on platelet aggregation mediated by arachidonic acid, U46619, a thromboxane (TX) A2 mimic, or thrombin, suggesting that paclitaxel may strongly inhibit collagenmediated signal transduction. In accordance with these findings, paclitaxel blocked collageninduced cytosolic calcium mobilization, arachidonic acid liberation, and serotonin secretion. In addition, it inhibited arachidonic acid-mediated platelet aggregation by about 37% by interfering with TXA2 synthase as measured by the formation of arachidonic acid-mediated TXA2 and prostaglandin D2, as well as cyclooxygenase-1 and TXA2 synthase activity assays. Taken together, these results point to a cellular mechanism for the anti-platelet activity of paclitaxel through the inhibition of TXA2 synthase and cytosolic calcium mobilization. This may contribute to the beneficial effects of paclitaxel on the cardiovascular system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akiba, S., Nagatomo, R., Ishimoto, T., and Sato, T., Effect of berbamine on cytosolic phospholipase A2 activation in rabbit platelets. Eur. J. Pharmacol., 291, 343–350 (1995).
Berridge, M. J., Inositol triphosphate and calcium signaling. Nature, 361, 315–325 (1993).
Blockmans, D., Deckmyn, H., and Vermylen, J., Platelet activation. Blood Rev., 9, 143–156 (1995).
Born, G. V. and Cross, M. J., The aggregation of blood platelets. J. Physiol., 168, 178–195 (1963).
Coleman, R. A., Smith, W. L., and Narumiya, S., International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205–229 (1994).
Cowan, D. H., Platelet adherence to collagen: role of prostaglandin-thromboxane synthesis. Br. J. Haematol., 49, 425–434 (1981).
Cowan, D. H., Robertson, A. L., Shook, P., and Giroski, P., Platelet adherence to collagen: role of plasma, ADP, and divalent cations. Br. J. Haematol., 47, 257–267 (1981).
Farndale, R. W., Sixma, J. J., Barnes, M. J., and De Groot, P. G., The role of collagen in thrombosis and hemostasis. J. Thromb. Haemost., 2, 561–573 (2004).
Gabryel, B., Chalimoniuk, M., Stolecka, A., Waniek, K., Langfort, J., and Malecki, A., Inhibition of arachidonic acid release by cytosolic phospholipase A2 is involved in the antiapoptotic effect of FK506 and cyclosporin A on astrocytes exposed to simulated ischemia in vitro. J. Pharmacol. Sci., 102, 77–87 (2006).
Genton, E., Clagett, G. P., and Salzman, E. W., Antithrombotic therapy in peripheral vascular disease. Chest, 89, 75S–81S (1986).
Gibbins, J. M., Platelet adhesion signalling and the regulation of thrombus formation. J. Cell Sci., 117, 3415–3425 (2004).
Godfraind, T., Calcium antagonists and vasodilation. Pharmacol. Ther., 64, 37–75 (1994).
Goldman, B., Blanke, H., and Wolinsky, H., Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase: a new catheter approach. Atherosclerosis, 65, 215–225 (1987).
Grande, P., Grauholt, A. M., and Madsen, J. K., Unstable angina pectoris. Platelet behavior and prognosis in progressive angina and intermediate coronary syndrome. Circulation, 81, I16–I19 (1990).
Grem, J. L., Tutsch, K. D., Simon, K. J., Alberti, D. B., Willson, J. K. V., Tormey, D. C., Swaminathan, S., and Trump, D. L., Phase I study of taxol administered as a short IV infusion daily for 5 days. Cancer Treat. Rep., 71, 1179–1184 (1987).
Heemskerk, J. W. M. and Sage, O., Calcium signaling in platelets and other cells. Platelets, 5, 295–316 (1994).
Herdeg, G., Oberhoff, M., and Karsch, K. R., Antiproliferative stent coatings: Taxol and related compounds. Semin. Interv. Cardiol., 3, 197–199 (1998).
Hjemdahl-Monsen, C. E., Lewis, H. D., Cairns, J., Chesebro, J. H., and Fuster, V., Role of antithrombotic therapy in unstable angina, myocardial infarction and sudden death. J. Am. Coll. Cardiol., 8, 67B–75B (1986).
Holmsen, H. and Dangelmarier, C. A.. Measurement of secretion of serotonin. Methods Enzymol., 169, 205–210 (1989).
Horwitz, S. B., Mechanism of action of taxol. Trends Pharmacol. Sci., 13, 134–136 (1992).
Jin, Y. R., Cho, M. R., Ryu, C. K., Chung, J. H., Yuk, D. Y., Hong, J. T., Lee, K. S., Lee, J. J., Lee, M. Y., Lim, Y., and Yun, Y. P., Antiplatelet activity of J78 (2-chloro-3-[2′-bromo, 4′-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization. J. Pharmacol. Exp. Ther., 312, 214–219 (2005).
Jin, Y. R., Han, H. H., Zhang, Y. H., Lee, J. J., Lim, Y., Chung, J. H., and Yun, Y. P., Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis, 194, 144–152 (2007).
Jin, Y. R., Ryu, C. K., Moon, C. K., Cho, M. R., and Yun, Y. P., Inhibitory effects of J78, a newly synthesized 1,4-naphthoquinone derivative, on experimental thrombosis and platelet aggregation. Pharmacology, 70, 195–200 (2004).
Johnson, G. J., Leis, L. A., and Francis, G. S., Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets. Circulation, 73, 847–854 (1986).
Jordan, M. A., Mechanism of action of antitumour drugs that interact with microtubules and tubulin. Curr. Med. Chem., 2, 1–17 (2002).
Kris, M. G., O’Connell, J. P., Gralla, R. J., Wertheim, M. S., Parente, R. M., Schiff, P. B., and Young, C. W., Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat. Rep., 70, 605–607 (1986).
McNicol, A. and Shibou, T. S., Translocation and phosphorylation of cytosolic phospholipase A2 in activated platelets. Thromb. Res., 92, 19–26 (1998).
Needleman, P., Turk, J., Jakschik, B. A., Morrison, A. R., and Lefkowith, J. B., Arachidonic acid metabolism. Annu. Rev. Biochem., 55, 69–102 (1986).
Nieswandt, B. and Watson, S. P., Platelet-collagen interaction: is GPVI the central receptor? Blood, 102, 449–461 (2003).
Niiya, K., Hodson, E., and Bader, R., Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation: relationship to the binding of fibrinogen and platelet aggregation. Blood, 70, 475–483 (1987).
Oates, J. A., Hardman, J. G., Limbird, L. E., Molinoff, P. B., and Al., E., Antihypertensive agents and the drug therapy of hypertension. The pharmacological basis of therapeutics. 9th ed. McGraw-Hill, New York, pp. 80–808, (1996).
Parise, L. V., Venton, D. L., and Le Breton, G. C., Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. J. Pharmacol. Exp. Ther., 228, 240–244 (1984).
Pollock, W. K., Rink, T. J., and Irvine, R. F., Liberation of [3H] arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen. Biochem. J., 235, 869–877 (1986).
Purdon, A. D., Patelunas, D., and Smith, J. B., Evidence for the release of arachidonic acid through the selective action of phospholipase A2 in thrombin-stimulated human platelets. Biochim. Biophys. Acta, 920, 205–214 (1987).
Rowinsky, E. K. and Donehower, R. C., Paclitaxel (taxol). N. Engl. J. Med., 332, 1004–1014 (1995).
Sherman, D. G. and Hart, R. G., Thromboembolism and antithrombotic therapy in cerebrovascular disease. J. Am. Coll. Cardiol., 8, 88B–97B (1986).
Sixma, J. J., Van Zanten, G. H., Huizinga, E. G., Van Der Plas, R. M., Verkley, M., Wu, Y. P., Gros, P., and De Groot, P. G., Platelet adhesion to collagen: an update. Thromb. Haemost., 78, 434–438. (1997).
Steinhubl, S. and Moliterno, D. J., The role of the platelet in the pathogenesis of atherothrombosis. Am. J. Cardiovasc. Drugs, 5, 399–408 (2005).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lee, JJ., Yu, JY., Lee, JH. et al. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase. Arch. Pharm. Res. 33, 387–394 (2010). https://doi.org/10.1007/s12272-010-0307-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-010-0307-1